Cingulate, a company listed on the Nasdaq Capital Market under the symbol 'CING', has filed a prospectus supplement on September 3, 2024, to update its previous offering terms. The supplement amends the prior prospectus dated January 13, 2023, and its subsequent supplements, to increase the amount of common stock the company is eligible to sell. Under the revised terms, Cingulate may now offer and sell shares with an aggregate offering price of up to $3,870,000 through H.C. Wainwright & Co., LLC, acting as the sales agent. This new limit is in addition to the $11,323,947.19 worth of common stock already sold under the previous prospectus. The public float of Cingulate's common stock was valued at over $40 million as of September 3, 2024, based on the closing price of $17.69 per share on August 16, 2024. The last reported sale price of Cingulate's common stock was $7.89 per share on August 30, 2024.

Cingulate, a company listed on the Nasdaq Capital Market under the symbol 'CING', has filed a prospectus supplement on September 3, 2024, to update its previous offering terms. The supplement amends the prior prospectus dated January 13, 2023, and its subsequent supplements, to increase the amount of common stock the company is eligible to sell. Under the revised terms, Cingulate may now offer and sell shares with an aggregate offering price of up to $3,870,000 through H.C. Wainwright & Co., LLC, acting as the sales agent. This new limit is in addition to the $11,323,947.19 worth of common stock already sold under the previous prospectus. The public float of Cingulate's common stock was valued at over $40 million as of September 3, 2024, based on the closing price of $17.69 per share on August 16, 2024. The last reported sale price of Cingulate's common stock was $7.89 per share on August 30, 2024.